Target Corporation (TGT)
The Lowest-Beta Mega-Cap Just Got a $358 Target
Our 24/7 Wall St. price target for Apple (NASDAQ: AAPL | AAPL Price Prediction) is $358.99, implying 18.77% upside from the $302.25 close on August 12, 2026.
CoreWeave Is Growing Faster Than Almost Anyone. Here's Our Price Target
CoreWeave (NASDAQ: CRWV) is one of the fastest-growing infrastructure businesses in the public market.
Cisco Drops 7% on Gross Margin Fears: Five Firms Raise Cisco Price Target Anyway
Shares of Cisco Systems (NASDAQ:CSCO | CSCO Price Prediction) are down 7% to $115 Thursday morning after the company's fiscal Q4 2026 results delivered a beat and raise.
Target & 3 Retail Stocks Poised for an Earnings Beat This Season
Target, Costco, Dollar General and Ross Stores are positioned for potential earnings beats amid resilient demand, value focus and digital gains.
Is it Time to Take a Closer Look at Target Maturity ETFs?
Among the key benefits of the ETF wrapper is the wide range of tools it gives advisors and investors to build tailored fixed income portfolios. And given today's complex rate and inflation environment, it certainly helps to have a wide range of options available.
Can Boot Barn Reach Its Long-Term Target of 1,200 U.S. Stores?
BOOT is expanding rapidly, with 566 stores and plans to add 70 more in fiscal 2027, supporting its long-term U.S. growth strategy.
Rocket Lab Price Prediction: Record Backlog, Bigger Ambitions. Here's Our Price Target
Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) delivered a quarter that reframes the investment case.
Will Target (TGT) Beat Estimates Again in Its Next Earnings Report?
Target (TGT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside
Damora Therapeutics is advancing a differentiated portfolio targeting mutant calreticulin (mutCALR) in ET and MF, with three escalating mechanism programs. DMRA's lead candidate, DMR-001, offers up to 30x potency and 5x half-life over comparators, supporting convenient monthly subcutaneous dosing. CLARITY-101 trial design accelerates clinical evaluation, with proof-of-concept data expected mid-2027 and Phase 3 potentially starting mid-2028.
Target (TGT) Reports Next Week: Wall Street Expects Earnings Growth
Target (TGT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Revolution Medicines May Be Big Pharma's Next Takeover Target
Revolution Medicines (NASDAQ:RVMD | RVMD Price Prediction) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform a market cap of $44.1 billion.
Target Appoints Lowe's Veteran Chandhu Nair as First Chief AI Officer
Target has appointed its first chief artificial intelligence officer, the company said in a Tuesday (Aug. 11) article. Chandhu Nair will join the company on Aug. 24 and will bring greater focus and coordination to AI across the company, according to the article.
